Literature DB >> 18171347

Portosystemic pressure gradient during transjugular intrahepatic portosystemic shunt with Viatorr stent graft: what is the critical low threshold to avoid medically uncontrolled low pressure gradient related complications?

Hwan-Hoon Chung1, Mahmood K Razavi, Daniel Y Sze, Joan K Frisoli, Stephen T Kee, Michael D Dake, Jeffrey C Hellinger, Byung-Chul Kang.   

Abstract

BACKGROUND: Inappropriately decreased portosystemic pressure gradient (PSG) during transjugular intrahepatic portosystemic shunt (TIPS) can cause fatal complications but the critical low threshold of PSG is still not clear. The aim of the present study was to evaluate the critical low threshold of PSG during TIPS.
METHODS: Sixty-six patients with cirrhosis who successfully underwent de novo TIPS with Viatorr stent grafts were studied. Medically uncontrolled low pressure gradient (LPR) complication was defined as when a patient died, or when acute transplantation or a TIPS reduction procedure was performed due to refractory encephalopathy or the deterioration of hepatic function within 3 months after the procedure. For the determination of the risk group for medically uncontrolled LPR complications, the Child-Pugh score and the model of end-stage liver disease (MELD) score showing a 100% negative predictive value was decided on as a threshold for each score. The risk group was defined when either of both scores was higher than its threshold. For the determination of a critical low post-TIPS PSG, a value of post-TIPS PSG showing the highest discrimination power on the receiver operating characteristic (ROC) curve in the risk group was decided on as a critical low threshold of PSG. The medically uncontrolled LPR complication rates of the patients with the determined threshold or lower were evaluated for the risk group.
RESULTS: Medically uncontrolled LPR complications developed in nine patients (13.6%). Five patients died and four patients had TIPS reduction procedures. Patients with more than 10 on the Child-Pugh score or more than 14 on the MELD score were determined to be the risk group and 34 patients were included. The critical lower threshold of the post-TIPS PSG showing the highest discrimination power on the ROC curve was 5 mmHg (sensitivity 100%, specificity 72%), and the medically uncontrolled LPR complication rates of the patients with 5 mmHg or lower on the post-TIPS PSG were 56.3% (9/16) in the risk group.
CONCLUSIONS: The critical threshold of the post-TIPS PSG to avoid the medically uncontrolled LPR complications of TIPS was >5 mmHg. The PSG should not be reduced below this level in the risk group.

Entities:  

Mesh:

Year:  2008        PMID: 18171347     DOI: 10.1111/j.1440-1746.2006.04697.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  16 in total

Review 1.  Transjugular intrahepatic portosystemic shunt complications: prevention and management.

Authors:  Paul V Suhocki; Matthew P Lungren; Baljendra Kapoor; Charles Y Kim
Journal:  Semin Intervent Radiol       Date:  2015-06       Impact factor: 1.513

2.  Parallel TIPS for treatment of refractory ascites and hepatic hydrothorax.

Authors:  Ahmad Parvinian; Ron C Gaba
Journal:  Dig Dis Sci       Date:  2013-04-27       Impact factor: 3.199

3.  Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites.

Authors:  Ahmad Parvinian; James T Bui; M Grace Knuttinen; Jeet Minocha; Ron C Gaba
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

Review 4.  Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes.

Authors:  Francesco Vizzutti; Filippo Schepis; Umberto Arena; Fabrizio Fanelli; Stefano Gitto; Silvia Aspite; Laura Turco; Gabriele Dragoni; Giacomo Laffi; Fabio Marra
Journal:  Intern Emerg Med       Date:  2020-01-09       Impact factor: 3.397

5.  Assessment of Clinical Outcomes, Clinical Manifestations, and Risk Factors for Hepatic Infarction After Transjugular Intrahepatic Portosystemic Shunt Placement (TIPS): A Retrospective Comparative Study.

Authors:  Tisileli S Tuifua; Sasan Partovi; Erick M Remer; Jonathan Ragheb; Jennifer A Bullen; Michael W Kattan; Baljendra Kapoor
Journal:  Cardiovasc Intervent Radiol       Date:  2022-07-18       Impact factor: 2.797

Review 6.  Imaging-guided interventions modulating portal venous flow: Evidence and controversies.

Authors:  Roberto Cannella; Lambros Tselikas; Fréderic Douane; François Cauchy; Pierre-Emmanuel Rautou; Rafael Duran; Maxime Ronot
Journal:  JHEP Rep       Date:  2022-04-04

7.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

8.  Role of TIPS in Improving Survival of Patients with Decompensated Liver Disease.

Authors:  Sundeep J Punamiya; Deepak N Amarapurkar
Journal:  Int J Hepatol       Date:  2011-07-02

9.  A method for revision of a foreshortened transjugular intrahepatic portosystemic shunt (TIPS) stent using transhepatic trans-stent access.

Authors:  Christian Nguyen; Taylor Robinson; Anthony J Borgmann; Christopher Baron; Reza A Imani
Journal:  Radiol Case Rep       Date:  2021-07-01

Review 10.  North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.

Authors:  Justin R Boike; Bartley G Thornburg; Sumeet K Asrani; Michael B Fallon; Brett E Fortune; Manhal J Izzy; Elizabeth C Verna; Juan G Abraldes; Andrew S Allegretti; Jasmohan S Bajaj; Scott W Biggins; Michael D Darcy; Maryjane A Farr; Khashayar Farsad; Guadalupe Garcia-Tsao; Shelley A Hall; Caroline C Jadlowiec; Michael J Krowka; Jeanne Laberge; Edward W Lee; David C Mulligan; Mitra K Nadim; Patrick G Northup; Riad Salem; Joseph J Shatzel; Cathryn J Shaw; Douglas A Simonetto; Jonathan Susman; K Pallav Kolli; Lisa B VanWagner
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-15       Impact factor: 13.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.